L'intérêt à découvert pour Surf Air Mobility donne aux investisseurs une idée du degré auquel les investisseurs parient sur la baisse de l'action de Surf Air Mobility. Les données sur l'intérêt à découvert sont mises à jour toutes les deux semaines.

Surf Air Mobility (NYSE:SRFM) Stock, Rapport sur les intérêts à découvert

Surf Air Mobility

Surf Air Mobility Inc. Common Stock

Surf Air Mobility Inc provides a regional air mobility platform to connect communities sustainably. The company is an electric aviation and air travel company expanding the category of regional air travel and reinventing flying through electrification. The company is building a regional air mobility ecosystem to sustainably connect the world's communities. It generates revenue through air mobility services.

Surf Air Mobility Inc

Counterpoint Research has cut growth expectations for <a href="https://www.benzinga.com/topic/smartphones" target="_blank" rel="noreferrer noopener">global smartphone shipments</a> in 2025 to 1.9% on Wednesday, down from 4.2% previously, citing Trump administration tariff-related uncertainties.
The firm also revised shipment growth from China down to near flat and expects Apple Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AAPL#NASDAQ">AAPL</a>) and Samsung Electronics (OTC:<a class="ticker" href="https://www.benzinga.com/stock/SSNLF#OTC">SSNLF</a>)&nbsp;shipments to slow as the companies pass the <a target="_blank" href="https://www.counterpointresearch.com/report/market-monitor-smartphone-brand-shipment-analysis-by-model-q1-2025" rel="noreferrer noopener">cost burden on</a> consumers.
President Trump announced a series of tariffs on its trading partners on April 2 to encourage manufacturing in the U.S.
Also Read: <a target="_blank" href="https://www.benzinga.com/news/global/25/04/44796659/apple-tops-global-smartphone-sales-with-19-share-boosted-by-iphone-16e-emerging-market-growth" rel="noreferrer noopener">Apple Tops Global Smartphone Sales With 19% Share, Boosted By iPhone 16e, Emerging Market Growth</a>
On May 12, Beijing and Washington&nbsp;<a target="_blank" href="https://www.benzinga.com/government/regulations/25/05/45676270/chinese-stocks-soar-as-us-court-blocks-trump-tariffs" rel="noreferrer noopener">agreed to lower&nbsp;tariffs</a> on each other's products, temporarily offering relief to the stock market. The deal reduced U.S. levies of 145% on most Chinese imports to 30%, while China's 125% duties on U.S. goods will drop to 10% for 90 days.
Last week, International Data Corporation (IDC) in its research report cut the 2025 <a href="https://www.benzinga.com/news/25/05/45708416/apple-iphone-shipment-could-decline-in-2025-as-tariff-competition-play-spoil-sport-idc" target="_blank" rel="noreferrer noopener">global smartphone shipment</a> growth outlook to 0.6% from 2.3%.
IDC expects China smartphone shipments to grow by 3% in 2025, driven by government subsidies.
In contrast,&nbsp;Apple&nbsp;is forecast to decline 1.9% in 2025 due to ongoing competition from&nbsp;Huawei, the overall economic slowdown, and the lack of subsidies for most of its models.
IDC expects the U.S. smartphone shipment to grow 1.9% in 2025, down from 3.3% in 2017, due to increased uncertainty and tariff-related price increases.
Meanwhile, Deepwater Research&#8217;s Gene Munster estimated that Apple has <a href="https://www.benzinga.com/markets/tech/25/06/45764870/apple-has-at-least-two-years-before-losing-customers-despite-its-several-ai-missteps-says-gene-munster-heres-why" target="_blank" rel="noreferrer noopener">about two years</a> to perfect its AI strategy, but it will require increased investments.
The AI features of smartphones are the<a target="_blank" href="https://www.benzinga.com/analyst-ratings/price-target/25/04/44613270/apple-set-for-strong-iphone-upgrade-cycle-driven-by-ai-analyst-says" rel="noreferrer noopener"> key deciding factor</a> determining their prospects.
<h2 class="wp-block-heading">Apple Stock Prediction For 2025</h2>
Equity research can be a valuable source of information for learning about a company's fundamentals. Analysts create financial models based on the fundamentals and expected future earnings of a company to arrive at a price target and recommendation for the stock.
Shares of Apple have an average 1-year price target of $238.79, representing an expected upside of 17.47%.
Because of differences in assumptions, analysts can arrive at very different price targets and recommendations. 3 analysts have bearish recommendations on Apple, while 21 analysts have bullish ratings. The street high price target from Wedbush is $325.0, while the street low from Jefferies is $167.88.
APPL&nbsp;Price Action:&nbsp;Apple stock is down 0.50% to $202.26 premarket at last check Tuesday.
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/analyst-stock-ratings/analyst-color/25/06/45756083/which-internet-software-stocks-is-jp-morgan-bullish-on" target="_blank" rel="noreferrer noopener">Which Internet Software Stocks Is JP Morgan Bullish On?</a></li>
</ul>
Image by Wongsakorn 2468 via Shutterstock

News

Tech

Trading Ideas

AAPL

SSNLF

Tariffs, AI And Trade War: Apple's Smartphone Growth To Take A Hit, Experts Say

WIIM

FUFU

BitFuFu shares are trading higher after the company provided monthly Bitcoin holdings and production updates for May.

Swedish biopharmaceutical company Camurus AB entered a collaboration and license agreement with Eli Lilly and Co. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LLY#NYSE">LLY</a>) on Tuesday.
Camurus granted Eli Lilly exclusive, worldwide rights to research, develop, manufacture, and commercialize <a href="https://www.benzinga.com/topic/weight-loss" target="_blank" rel="noreferrer noopener">long-acting incretin</a> products for cardiometabolic health based on Camurus&#8217; FluidCrystal technology.
The agreement <a target="_blank" href="https://www.camurus.com/media/press-releases/2025/camurus-and-lilly-enter-collaboration-and-license-agreement-for-long-acting-fluidcrystal-incretins/" rel="noreferrer noopener">comprises</a> up to four Lilly proprietary drug compounds, selected from dual GIP and GLP-1 receptor agonists, triple GIP, glucagon, and GLP-1 receptor agonists, and an option to include amylin receptor agonists.
Also Read: <a target="_blank" href="https://www.benzinga.com/25/05/45341500/eli-lillys-zepbound-shows-superior-weight-loss-over-novo-nordisks-wegovy-in-head-to-head-trial" rel="noreferrer noopener">Eli Lilly&#8217;s Zepbound Shows Superior Weight Loss Over Novo Nordisk&#8217;s Wegovy In Head-To-Head Trial</a>
Camurus' FluidCrystal technology is designed to deliver therapeutic levels of drug substance over extended periods – from days to months – with a single injection using a prefilled syringe or autoinjector pen.
Upon contact with bodily fluids in the tissue, the lipid solution transforms into a liquid crystalline gel that quickly and effectively encapsulates the active ingredient. The drug is slowly released as the liquid crystalline matrix gradually degrades in the tissue.
The technology is commercially and regulatory validated by market approvals and product sales in Europe, the US, and Australia.
In return for granting Lilly the license to use the FluidCrystal technology for the selected incretin drug compounds for cardiometabolic health, Camurus is eligible to receive up to&nbsp;$290 million&nbsp;in upfront, development, and regulatory milestone payments, $580 million in sales-based milestone payments, and tiered mid-single-digit royalties on global net product sales.
In May, Eli Lilly agreed to acquire&nbsp;SiteOne Therapeutics, Inc., a private biotechnology company developing small-molecule inhibitors of sodium channels to treat pain and other neuronal&nbsp;<a target="_blank" href="https://www.benzinga.com/general/biotech/25/05/45629147/breaking-the-pain-barrier-lillys-acquisition-of-siteone-aims-for-opioid-alternatives" rel="noreferrer noopener">hyperexcitability disorders</a>.
The transaction includes STC-004, a Phase 2 ready Nav1.8 inhibitor being&nbsp;studied for pain.
STC-004 may represent a next-generation, non-opioid treatment for patients suffering from chronic pain.
In May, Eli Lilly entered into a strategic global research collaboration and licensing agreement with Rznomics Inc., a South Korea-based biopharmaceutical company specializing <a href="https://www.benzinga.com/25/05/45450675/eli-lilly-collaborates-with-south-korea-based-rznomics-for-rna-editing-therapies-for-hearing-loss-treatment-in-over-13-billion-pact" target="_blank" rel="noopener">in RNA-based therapeutics</a>.
The agreement focuses on developing and commercializing RNA-editing therapies using Rznomics&#8217; proprietary trans-splicing ribozyme platform.
The collaboration&nbsp;<a target="_blank" href="https://www.prnewswire.com/news-releases/rznomics-enters-global-licensing-agreement-with-eli-lilly-for-rna-editing-therapeutics-302456852.html?tblci=GiCUX7wvU_AgmIIiQduNYr6JQuJQLy6SZJGvpyeZuCzyqiCN1VcoxvTN4f7-y-PqATDviEo" rel="noreferrer noopener">focuses</a>&nbsp;on discovering and developing RNA-editing therapeutics for sensorineural hearing loss. Rznomics will conduct early-stage research according to the jointly approved research plans, while Lilly will assume responsibility for further development and commercialization.
Price Action: At the last check on Wednesday, LLY stock was up 0.40% at $753.80 during the premarket session.
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/trading-ideas/dividends/25/06/45767454/autoliv-boosts-shareholder-returns-with-21-dividend-hike-new-2-5-billion-buyback-program" target="_blank" rel="noreferrer noopener">Autoliv Boosts Shareholder Returns With 21% Dividend Hike, New $2.5 Billion Buyback Program</a></li>
</ul>
Photo: Shutterstock

Biotech

Health Care

Mounjaro Maker Eli Lilly Taps Swedish Firm Camurus To Target Long-Acting Obesity Market In $870-Million Deal

Telsey Advisory Group analyst Dana Telsey maintains Victoria's Secret (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VSCO#NYSE">VSCO</a>) with a Market Perform and maintains $24 price target.

Price Target

Analyst Ratings

VSCO

Telsey Advisory Group Maintains Market Perform on Victoria's Secret, Maintains $24 Price Target

REVG

REV Group shares are trading higher after the company reported better-than-expected Q2 financial results and raised its FY25 sales guidance.

Competitive statewide RFP win provides a platform for efficient expansion within the state
TEL AVIV, Israel, June 4, 2025 /PRNewswire/ -- SuperCom (NASDAQ:&nbsp;SPCB),&nbsp;a global provider of secure solutions for the e-Government, IoT, and Cybersecurity sectors, announced today that it has been awarded a statewide technology procurement contract by the North Carolina Sheriff's Association, emerging as the only new electronic monitoring technology provider selected through this competitive RFP. This contract serves as a procurement vehicle to allow all counties in North Carolina to contract directly with SuperCom on preset terms, most of the time without an additional RFP process. This strategic win is another testament to the Company's rapid expansion across the North American public safety market.

Contracts

SPCB

SuperCom Wins Statewide Technology Procurement Contract With North Carolina Sheriff's Association As Sole New Electronic Monitoring Provider

YEXT

Yext shares are trading higher after the company raised its FY26 adjusted EPS guidance above estimates. Also, Needham reiterated a Buy rating on the stock.

Telsey Advisory Group analyst Dana Telsey maintains Steven Madden (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SHOO#NASDAQ">SHOO</a>) with a Market Perform and maintains $24 price target.

SHOO

Telsey Advisory Group Maintains Market Perform on Steven Madden, Maintains $24 Price Target

JFIN

Jiayin Group shares are trading higher after the company reported a year-over-year increase in its Q1 financial results.

Keybanc analyst Bradley Thomas reiterates Ollie's Bargain Outlet (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OLLI#NASDAQ">OLLI</a>) with a Overweight and maintains $135 price target.

Reiteration

OLLI

Keybanc Reiterates Overweight on Ollie's Bargain Outlet, Maintains $135 Price Target

Thor Industries shares are trading higher after the company reported better-than-expected Q3 financial results.

Telsey Advisory Group analyst Joseph Feldman maintains Dollar Tree (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DLTR#NASDAQ">DLTR</a>) with a Market Perform and maintains $95 price target.

DLTR

Telsey Advisory Group Maintains Market Perform on Dollar Tree, Maintains $95 Price Target

Keybanc analyst Bradley Thomas reiterates Dollar General (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DG#NYSE">DG</a>) from Sector Weight to Sector Weight.

Keybanc Reiterates Sector Weight on Dollar Generalto Sector Weight

MRUS

Merus shares are trading lower following its $300 million public offering announcement.

LITE

Lumentum Holdings shares are trading higher after the company raised its Q4 guidance. Additionally, Rosenblatt raised its price target on the stock from $94 to $105.

UBS analyst Karl Keirstead upgrades Snowflake (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SNOW#NYSE">SNOW</a>) from Neutral to Buy and raises the price target from $210 to $265.

Upgrades

SNOW

UBS Upgrades Snowflake to Buy, Raises Price Target to $265

ASAN

Asana shares are trading lower after the company issued FY26 guidance below estimates.

UBS analyst Anojja Shah initiates coverage on Sonoco Prods (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SON#NYSE">SON</a>) with a Neutral rating and announces Price Target of $48.

Initiation

UBS Initiates Coverage On Sonoco Prods with Neutral Rating, Announces Price Target of $48

Annamycin delivering better performance 7th line than would be expected even in 2nd line for monotherapy
Responders (Stable Disease or Partial Response) after 2 cycles of Annamycin showed improvement in OS and Progression Free Survival ("PFS")
Clinical Benefit Rate ("CBR") was 59.4% (n=32), comprised of 18 subjects with stable disease and 1 subject with a partial response
Potential to address 13,500 new incidents of STS each year and market opportunity expected to grow to $2.6B by 20301
On-demand video webcast with members of the Moleculin management team and internationally renowned Key Opinion Leaders available Thursday, June 5th
HOUSTON, June 04, 2025 (GLOBE NEWSWIRE) -- Moleculin Biotech, Inc., (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MBRX#NASDAQ">MBRX</a>) ("Moleculin" or the "Company"), a late-stage pharmaceutical company with a broad portfolio of drug candidates targeting hard-to-treat cancers and viruses, today reported positive topline efficacy results from its completed U.S. Phase 1B/2 clinical trial evaluating Annamycin for the treatment of soft tissue sarcoma lung metastases ("STS lung mets") (MB-107).
The MB-107 trial was a multi-center, open-label, single-arm monotherapy study that in Phase 1B determined the Maximum Tolerable Dose and Recommended Phase 2 Dose ("MTD", "RP2D" respectively) and safety of Annamycin and in Phase 2 explored the efficacy of Annamycin as a single agent for the treatment of subjects with STS lung mets for which chemotherapy was considered appropriate. For more information about the MB-107 trial visit <a href="https://www.globenewswire.com/Tracker?data=cIErFT_tsX39yiMPB49nWwCQtr1tUxq6RYQrO1PLLkBoMcgRmngECF7Tli-kjopu1eRuZxphaaV2VvIK4ZyejqFdWESfDHBbuhsXHq9zly4=">clinicaltrials.gov</a> and reference identifier NCT04887298.

General

MBRX

Moleculin Biotech Reports Phase 1B/2 Trial Results For Annamycin In Soft Tissue Sarcoma Lung Metastases, Showing Efficacy As 7th Line Monotherapy With 59.4% Clinical Benefit Rate, Improved Overall And Progression-Free Survival

Rivian Automotive (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RIVN#NASDAQ">RIVN</a>) is <a target="_blank" href="https://www.benzinga.com/topic/rivian" rel="noreferrer noopener">revamping the charging</a> experience for its electric vehicle customers.
The EV maker is launching a software update to its vehicles and smartphone app, offering more transparency about energy consumption and faster charging speeds, the Verge <a target="_blank" href="https://www.theverge.com/news/678005/rivian-ev-charging-software-update-battery-fast-charging" rel="noreferrer noopener">reported</a> on Tuesday.
Rivian&#8217;s Energy app will now include &#8220;Charging&#8221; for energy intake and &#8220;Energy Monitor&#8221; for energy output.
Also Read: <a target="_blank" href="https://www.benzinga.com/25/04/44934176/rivian-taps-ai-expert-aidan-gomez-to-drive-innovation-advanced-technology-integration" rel="noreferrer noopener">Tesla Rival Rivian Taps AI Expert Aidan Gomez To Drive Innovation</a>
The Charging tab shows a detailed breakdown of where the energy is going, including the battery and any connected accessories.
The Energy Monitor tab contains a new chart detailing how climate, outlets, and drive systems consume energy.
A new &#8220;Trip Target&#8221; feature provides charging recommendations when using navigation for a trip involving a charging stop to notify customers when they need to charge for the rest of the journey. 
Rivian is also adding a feature to precondition the battery on demand. The company obtained faster DC charging via a software update for its first- and second-generation EVs by optimizing battery temperatures in simulation.
Wassym Bensaid, Rivian&#8217;s chief software officer, told the Verge that it will roll out a new &#8220;Smart Charging&#8221; feature in July that allows customers to time their home-charging sessions.
In 2025, Rivian will launch a new bidirectional charging feature that enables users to utilize their vehicles as mobile power generators to send power to electronic devices.
Rivian stock surged over 28% in the last 12 months despite challenges associated with public EV charging, federal spending on charging installations, and the Trump administration&#8217;s tariff policies.
Despite mounting concerns over global trade tensions and tariffs, the company <a href="https://www.benzinga.com/markets/equities/25/05/45243985/rivian-holds-firm-on-45k-r2-price-despite-tariff-pressures-ceo-rj-scaringe-says-its-important-for-us-as-ev-maker-tops-q1-estimates" target="_blank" rel="noreferrer noopener">remains committed to</a> the $45,000 starting price for the upcoming R2 electric vehicle. It expects per-unit tariff impacts of approximately $2,000 for 2025.
Price Action:&nbsp;Rivian shares are trading higher by 0.97% at $14.51 premarket at last check Wednesday.
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/markets/large-cap/25/06/45745834/nio-stock-drops-after-q1-results-and-outlook-disappoints-the-street-margins-shrink" target="_blank" rel="noreferrer noopener">Nio Stock Drops After Q1 Results And Outlook Disappoints The Street, Margins Shrink</a></li>
</ul>
Photo: Shutterstock

RIVN

Rivian EVs Just Got Smarter: New App Tracks Energy Use And Speeds Up Charging

Press Releases

Surf Air Mobility Strengthens Aviation Leadership Team with Key Executive Appointments

Surf Air Mobility Announces Launch Customers for SurfOS™ Software

Surf Air Mobility to Announce Fourth Quarter and Year End 2024 Financial Results on March 18, 2025

Surf Air Mobility Reports Fourth Quarter and Full Year 2024 Financial Results

Surf Air Mobility Announces $5 Million Registered Direct Offering of Common Stock

Surf Air Mobility Closes $5 Million Registered Direct Offering of Common Stock

Surf Air Mobility to Announce First Quarter 2025 Financial Results on May 13, 2025

Mokulele Airlines and Japan Airlines Announce New Interline Agreement

Surf Air Mobility to Present at the Third Annual Jefferies eVTOL / AAM Summit

Surf Air Mobility Announces $1 Million Purchase of Company Stock by Co-Founder

PLTR

SRFM

American Airlines Group, Inc. - Common Stock

American Airlines Group

Allegiant Travel

Alaska Air Gr

Blade Air Mobility, Inc. - Class A Common Stock

Blade Air Mobility

Copa Holdings

Delta Air Lines

flyExclusive

JetBlue Airways Corporation - Common Stock

JetBlue Airways

Joby Aviation

Jet AI

LATAM Airlines Group S.A. American Depositary Shares (each representing two thousand (2,000) shares of Common Stock)

LATAM Airlines Group

Southwest Airlines

Mesa Air Group

Ryanair Holdings plc - American Depositary Shares, each representing five Ordinary Shares

Ryanair Hldgs

SkyWest

Sun Country Airlines Holdings, Inc. - Common Stock

Sun Country Airlines

Volato Group

United Airlines Holdings, Inc. - Common Stock

United Airlines Holdings

Frontier Group Holdings, Inc. - Common Stock

Frontier Group Holdings

Wheels Up Experience Inc. Class A Common Stock

Wheels Up Experience

Controladora Vuela Compania de Aviacion, S.A.B. de C.V. American Depositary Shares, each representing ten (10) Ordinary Participation Certificates

Comments

Surf Air Mobility

Intérêt court

Surf Air Mobility (NYSE:SRFM) Stock, Rapport sur les intérêts à découvert

Les gens regardent aussi

Notizie

PARTENAIRE / CONTRIBUTEUR

BENZINGA MONDIAL